Current Good Manufacturing Practice; Amendment of Certain Requirements For Finished Pharmaceuticals; Withdrawal, 68111-68113 [E7-23271]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Proposed Rules
68111
Actions
Compliance
Procedures
(1) Inspect/check the rudder, aileron, and rudder-aileron interconnect rigging; correct any
out-of-rig condition; and replace the attaching
hardware for the rudder-aileron interconnect
arm.
At whichever occurs first:
(i) Within the next 25 hours time-in-service (TIS) after the effective date of this
AD; or
(ii) Within the next 3 months after the effective date of this AD.
At whichever occurs later:
(i) Within 10 days after the inspection required in paragraph (e)(1) of this AD;
or
(ii) Within 10 days after the effective date
of this AD.
Follow Cirrus Service Bulletin No. SB 2X–27–
14 R3, Issued: May 9, 2007, Revised: October 10, 2007.
(2) Only if you find an out-of-rig condition: Report to the FAA any out-of-rig conditions discovered as a result of the inspection required
by paragraph (e)(1) of this AD on the form in
Figure 1 of this AD. The Office of Management and Budget (OMB) approved the information contained in this regulation under the
provisions of the Paperwork Reduction Act
and assigned OMB Control Number 2120–
0056.
Note: Temporary revisions to the airplane
maintenance manuals (AMM), SR20 AMM
Temporary Revision No. 27–1 and SR22
AMM Temporary Revision No. 27–1, both
Send the form (Figure 1 of this AD) to FAA,
Manufacturing Inspection District Office,
6020 28th Avenue South, Room 103, Minneapolis, Minnesota, 55450–2700; telephone (612) 713–4366; facsimile (612)
713–4365.
dated October 10, 2007, contain information
pertaining to this subject.
DOCKET NO. FAA–2007–28246 INSPECTION REPORT
[Report only if you find an out-of-rig condition]
1. Inspection Performed By:
2. Telephone:
3. Aircraft Model:
4. Airplane Serial Number:
5. Aircraft Total Hours Time-in-Service:
6. Date of inspection required in paragraph (e)(1) of this AD:
7a. Do any of the aircraft logs contain entries describing flight control
system maintenance, preventative maintenance, or alteration:
7b. If Yes, copy the log book entry(s) and include the date of the entry.
llYes llNo
8. Inspection Results: (Report only if an out-of-rig condition is found, and describe the out-of-rig condition as accurate and detailed as possible):
9. Corrective Action Taken:
Send to:
Federal Aviation Administration
Manufacturing Inspection District Office 6020 28th Avenue South, Room 103
Minneapolis, Minnesota 55450–2700
Telephone (612) 713–4366
Facsimile (612) 713–4365
mstockstill on PROD1PC66 with PROPOSALS
Alternative Methods of Compliance
(AMOCs)
(g) The Manager, Chicago Aircraft
Certification Office (ACO), FAA, has the
authority to approve AMOCs for this AD, if
requested using the procedures found in 14
CFR 39.19. Send information to ATTN: Wess
Rouse, Aerospace Engineer, 2300 East Devon
Avenue, Room 107, Des Plaines, Illinois
60018; telephone: (847) 294–8113; fax: (847)
294–7834. Before using any approved AMOC
on any airplane to which the AMOC applies,
notify your appropriate principal inspector
(PI) in the FAA Flight Standards District
Office (FSDO), or lacking a PI, your local
FSDO.
Related Information
(h) To get copies of the service information
referenced in this AD, contact Cirrus Design
VerDate Aug<31>2005
17:10 Dec 03, 2007
Jkt 214001
Corporation, 4515 Taylor Circle, Duluth,
Minnesota 55811; telephone: (218) 727–2737;
Internet address: https://
www.cirrusdesign.com. To view the AD
docket, go to the U.S. Department of
Transportation, Docket Operations, M–30,
West Building Ground Floor, Room W12–
140, 1200 New Jersey Avenue, SE.,
Washington, DC 20590, or on the Internet at
https://dms.dot.gov. The docket number is
Docket No. FAA–2007–28246; Directorate
Identifier 2007–CE–048–AD.
Issued in Kansas City, Missouri, on
November 28, 2007.
Patrick R. Mullen,
Acting Manager, Small Airplane Directorate,
Aircraft Certification Service.
[FR Doc. E7–23456 Filed 12–3–07; 8:45 am]
BILLING CODE 4910–13–P
PO 00000
Frm 00006
Fmt 4702
Sfmt 4702
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 210 and 211
[Docket No. 1995N–0362]
Current Good Manufacturing Practice;
Amendment of Certain Requirements
For Finished Pharmaceuticals;
Withdrawal
AGENCY:
Food and Drug Administration,
HHS
ACTION:
Proposed rule; withdrawal.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
E:\FR\FM\04DEP1.SGM
04DEP1
68112
Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Proposed Rules
withdrawal of a proposed rule
published in the Federal Register of
May 3, 1996 (61 FR 20103) (the May
1996 proposed rule). The May 1996
proposed rule would have amended
certain requirements of the current good
manufacturing practice (CGMP)
regulations for finished
pharmaceuticals. These proposed
changes would have clarified certain
manufacturing, quality control, and
documentation requirements and would
have updated the requirements for
process and methods validation. In light
of more recent scientific and technical
advances and evolving quality systems
and risk management concepts, FDA
concludes that, at this time, it is
appropriate to withdraw the May 1996
proposed rule and newly evaluate the
issues raised in that proposal.
DATES: The proposed rule is withdrawn
on December 4, 2007.
FOR FURTHER INFORMATION CONTACT:
Mary Malarkey, Center for Biologics
Evaluation and Research (HFM–
600), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852–1448,
301–827–6190, or
Dennis Bensley, Center for Veterinary
Medicine (HFV–140), Food and
Drug Administration, 7500 Standish
Pl., Rockville, MD 20855, 301–827–
6956, or
Frederick Blumenschein, Center for
Drug Evaluation and Research
(HFD–326), Food and Drug
Administration, 11919 Rockville
Pike, Rockville, MD 20852, 301–
827–9022.
SUPPLEMENTARY INFORMATION:
mstockstill on PROD1PC66 with PROPOSALS
I. Background
In the Federal Register of May 3, 1996
(61 FR 20103), FDA proposed to amend
certain requirements of the CGMP
regulations for finished pharmaceuticals
in parts 210 and 211 (21 CFR parts 210
and 211) to clarify certain
manufacturing, quality control, and
documentation requirements so that the
regulations would more accurately
reflect the prevailing CGMP. FDA
received approximately 1,500 comments
on the proposed rule. (See section III of
this document, Comments on the May
1996 Proposed Rule).
After publication of the May 1996
proposed rule, FDA began to reconsider
its approach to regulation of CGMP,
consistent with changes occurring in
other industries and in other countries.
This change in approach is summarized
in the following paragraphs.
In August 2002, FDA announced a
significant new initiative to enhance
and modernize regulation of
VerDate Aug<31>2005
17:10 Dec 03, 2007
Jkt 214001
pharmaceutical manufacturing quality,
the Pharmaceutical CGMPs for the 21st
Century initiative (21st Century
initiative). As a part of the 21st Century
initiative, FDA created a CGMP
Harmonization Analysis working group
to analyze internal and external CGMP
requirements, including those related to
quality systems. The working group
performed a formal analysis of parts 210
and 211 compared with other
regulations, such as the FDA Medical
Device Quality System Requirements,
the FDA Food Hazard Analysis and
Critical Control Points requirements,
and the drug GMPs of the European
Union, to identify the differences and
consider the value of adding or
changing the current regulations in light
of these more recently developed and
related product manufacturing
standards.
Based on the working group’s
analysis, the agency decided that a
different approach to revising the CGMP
regulations was appropriate, and has
decided to withdraw the proposed rule.
II. New Approach to Revising FDA’s
CGMP Regulations
The emphasis of the new approach to
CGMP arising from the 21st Century
Initiative will be to encourage timely
detection of and response to emerging
adverse trends or indications that
product quality has been compromised,
to provide further clarity and modernize
the regulations, and to harmonize
various aspects of parts 210 and 211
both internationally and with other
agency regulations.1
The agency has determined that the
current CGMP regulations (parts 210
and 211) provide a degree of flexibility
that will permit the agency to continue
to modernize its approach to regulation
of CGMP. The agency has also
concluded that, as stated in the final
report on the 21st Century initiative,
given this new approach to regulation of
pharmaceutical CGMP, it would be
preferable to revise the CGMP
regulations in an incremental fashion,
rather than using the comprehensive
approach taken in the May 1996
proposed rule. After careful
consideration, FDA concludes that at
this time, it is appropriate to withdraw
the May 1996 proposed rule and newly
evaluate the issues raised in that
proposal in the context of more recent
scientific and technical advances and
quality systems and risk management
concepts.
1See Pharmaceutical CGMPs for the 21st
Century—A Risk Based Approach; Final Report,
September, 2004; available at https://www.fda.gov/
cder/gmp/gmp2004/GMP_finalreport2004.htm.
PO 00000
Frm 00007
Fmt 4702
Sfmt 4702
We plan to revise the CGMP
regulations using a more incremental
approach. As part of the FDA’s
incremental approach to revising our
CGMP regulations, we are publishing a
direct final rule (and a companion
proposed rule) elsewhere in this issue of
the Federal Register that will, when
finalized, clarify and modernize certain
provisions in parts 210 and 211. That
direct final rule and proposed rule
include some of the minor changes to
CGMP that were originally proposed in
1996.
III. Comments on the May 1996
Proposed Rule
FDA received approximately 1,500
comments on the May 1996 proposed
rule from 116 pharmaceutical
companies, attorneys, consultants, trade
associations, and generic companies.
The most significant topics on which
FDA received comments are
summarized as follows:
• Approximately 298 comments
addressed the proposed new section on
process validation (§ 211.220). The
volume and variety of comments and
suggestions indicated to FDA that the
new section, as proposed, did not
provide the clarification intended.
• Approximately 102 comments were
directed at the proposed changes to
§ 211.110 on sampling and testing of inprocess materials and drug products,
which would have added new inprocess sampling and validation
requirements with respect to blend
uniformity. The bulk of these comments
questioned the need for additional
testing and sampling requirements in
§ 211.110, because other sections of the
current rule already require
scientifically sound sampling plans and
representative samples.
• Approximately 112 comments
discussed proposed revisions to
§ 211.192 on the production, control,
and laboratory review, and investigation
of discrepancies. The May 1996
proposed rule required written
procedures to be established for the
review of certain records and
investigation of unexplained
discrepancies. Many of these comments
recommended that these investigations
and reviews should be used to
proactively prevent (potential) future
problems rather than being used only to
retroactively identify manufacturing
discrepancies.
• A number of comments to the rule
were submitted by the compressed
medical gas industry, which
communicated concerns regarding the
applicability to the compressed medical
gas industry of the proposed changes to
CGMP.
E:\FR\FM\04DEP1.SGM
04DEP1
Federal Register / Vol. 72, No. 232 / Tuesday, December 4, 2007 / Proposed Rules
• Approximately 70 comments were
received regarding the proposed new
§ 211.240 on control of chemical and
physical contaminants. Many of the
comments stated that the rule should be
revised to better describe how
contaminants will be identified and to
provide allowances for threshold levels
or limits of contaminants.
Overall, the comments were
constructive, informative, and
addressed nearly every area of the May
1996 proposed rule. Although we do not
plan to publish specific responses to
each of these comments, we will take
these comments into account as we
proceed to make incremental changes to
parts 210 and 211.
IV. Withdrawal of the Proposed Rule
For the reasons described in this
document, FDA is withdrawing the
proposed rule published on May 3, 1996
(61 FR 20103).
Dated: November 26, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–23271 Filed 12–3–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 210 and 211
[Docket No. 2007N–0280]
Amendment to the Current Good
Manufacturing Practice Regulations for
Finished Pharmaceuticals; Companion
Document to the Direct Final Rule
AGENCY:
Food and Drug Administration,
HHS.
mstockstill on PROD1PC66 with PROPOSALS
ACTION:
Proposed rule.
SUMMARY: The Food and Drug
Administration (FDA) is publishing this
companion proposed rule to the direct
final rule, published elsewhere in this
issue of the Federal Register, which is
intended to amend certain sections of
the regulations as the first phase of an
incremental approach to modifying the
current good manufacturing practice
(CGMP) regulations for finished
pharmaceuticals.
DATES: Submit written or electronic
comments on or before February 19,
2008.
ADDRESSES: You may submit comments,
identified by Docket No. 2007N–0280,
by any of the following methods:
Electronic Submissions
Submit electronic comments in the
following ways:
VerDate Aug<31>2005
17:10 Dec 03, 2007
Jkt 214001
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Agency Web site: https://
www.fda.gov/dockets/ecomments.
Follow the instructions for submitting
comments on the agency Web site.
Written Submissions
Submit written submissions in the
following ways:
• FAX: 301–827–6870.
• Mail/Hand delivery/Courier [For
paper, disk, or CD–ROM submissions]:
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852.
To ensure more timely processing of
comments, FDA is no longer accepting
comments submitted to the agency by email. FDA encourages you to continue
to submit electronic comments by using
the Federal eRulemaking Portal or the
agency Web site, as described
previously, in the ADDRESSES portion of
this document under Electronic
Submissions.
Instructions: All submissions received
must include the agency name and
Docket No(s). and Regulatory
Information Number (RIN) (if a RIN
number has been assigned) for this
rulemaking. All comments received may
be posted without change to https://
www.fda.gov/ohrms/dockets/
default.htm, including any personal
information provided. For additional
information on submitting comments,
see the ‘‘Comments’’ heading of the
SUPPLEMENTARY INFORMATION section of
this document.
Docket: For access to the docket to
read background documents or
comments received, go to https://
www.fda.gov/ohrms/dockets/
default.htm and insert the docket
number(s), found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Mary Malarkey, Center for Biologics
Evaluation and Research (HFM–
600), Food and Drug
Administration, 1401 Rockville
Pike, Rockville, MD 20852–1448,
301–827–6190, or
Dennis Bensley, Center for Veterinary
Medicine (HFV–140), Food and
Drug Administration, 7500 Standish
Pl., Rockville, MD 20855, 301–827–
6956, or
Frederick Blumenschein, Center for
Drug Evaluation and Research
(HFD–326), Food and Drug
Administration, 11919 Rockville
PO 00000
Frm 00008
Fmt 4702
Sfmt 4702
68113
Pike, Rockville, MD 20852, 301–
827–9022.
SUPPLEMENTARY INFORMATION:
I. Background
Since the development of the CGMP
regulations in 1962, FDA has balanced
the need for easily understood
minimum standards with the need to
encourage innovation and the
development of improved
manufacturing technologies. We strive
to give manufacturers latitude to
determine how to achieve the level of
control necessary for CGMP compliance,
recognizing that, in some instances,
more direction from FDA is necessary to
provide a uniform standard to the entire
industry or because of the potential for
harm or the narrow range of acceptable
means to accomplish a particular CGMP
objective. FDA periodically reassesses
and revises the CGMP regulations to
accommodate advances in technology
that further safeguard the drug
manufacturing process and the public
health. As technology and scientific
knowledge related to CGMP evolve, so
does understanding of the material,
equipment, and process variables, as
well as the operational procedures and
oversight methods that must be defined
and controlled to achieve assurance of
drug product quality.
In 1996, as part of this reassessment
process, FDA proposed to amend certain
requirements of the CGMP regulations
for finished pharmaceuticals to clarify
certain manufacturing, quality control,
and documentation requirements, and
to ensure that the regulations more
accurately encompass current industry
practice (61 FR 20103, May 3, 1996)
(1996 proposed rule)). Subsequently, as
a part of the risk-based pharmaceutical
CGMPs for the 21st century initiative,
FDA created a CGMP Harmonization
Analysis Working Group (CGMP
Working Group) to analyze related
CGMP requirements in effect in the
United States and internationally,
including those related to quality
systems. The CGMP Working Group
compared parts 210 amd 211 (21 CFR
parts 210 and 211) with the GMPs of the
European Union (EU), as well as other
FDA regulations (e.g., the Quality
Systems Regulation, 21 CFR part 820) to
identify the differences and consider the
value of supplementing or changing the
current regulations. Based on the CGMP
Working Group’s analysis, we decided
to take an incremental approach to
modifying parts 210 and 211 (see https://
www.fda.gov/cder/gmp/gmp2004/
GMP_finalreport2004.htm#_
Toc84065744).
Because of this change in approach,
FDA decided not to finalize the 1996
E:\FR\FM\04DEP1.SGM
04DEP1
]]>Agencies
[Federal Register Volume 72, Number 232 (Tuesday, December 4, 2007)]
[Proposed Rules]
[Pages 68111-68113]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23271]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 210 and 211
[Docket No. 1995N-0362]
Current Good Manufacturing Practice; Amendment of Certain
Requirements For Finished Pharmaceuticals; Withdrawal
AGENCY: Food and Drug Administration, HHS
ACTION: Proposed rule; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
[[Page 68112]]
withdrawal of a proposed rule published in the Federal Register of May
3, 1996 (61 FR 20103) (the May 1996 proposed rule). The May 1996
proposed rule would have amended certain requirements of the current
good manufacturing practice (CGMP) regulations for finished
pharmaceuticals. These proposed changes would have clarified certain
manufacturing, quality control, and documentation requirements and
would have updated the requirements for process and methods validation.
In light of more recent scientific and technical advances and evolving
quality systems and risk management concepts, FDA concludes that, at
this time, it is appropriate to withdraw the May 1996 proposed rule and
newly evaluate the issues raised in that proposal.
DATES: The proposed rule is withdrawn on December 4, 2007.
FOR FURTHER INFORMATION CONTACT:
Mary Malarkey, Center for Biologics Evaluation and Research (HFM-
600), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD
20852-1448, 301-827-6190, or
Dennis Bensley, Center for Veterinary Medicine (HFV-140), Food and
Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-
6956, or
Frederick Blumenschein, Center for Drug Evaluation and Research
(HFD-326), Food and Drug Administration, 11919 Rockville Pike,
Rockville, MD 20852, 301-827-9022.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of May 3, 1996 (61 FR 20103), FDA proposed
to amend certain requirements of the CGMP regulations for finished
pharmaceuticals in parts 210 and 211 (21 CFR parts 210 and 211) to
clarify certain manufacturing, quality control, and documentation
requirements so that the regulations would more accurately reflect the
prevailing CGMP. FDA received approximately 1,500 comments on the
proposed rule. (See section III of this document, Comments on the May
1996 Proposed Rule).
After publication of the May 1996 proposed rule, FDA began to
reconsider its approach to regulation of CGMP, consistent with changes
occurring in other industries and in other countries. This change in
approach is summarized in the following paragraphs.
In August 2002, FDA announced a significant new initiative to
enhance and modernize regulation of pharmaceutical manufacturing
quality, the Pharmaceutical CGMPs for the 21st Century initiative (21st
Century initiative). As a part of the 21st Century initiative, FDA
created a CGMP Harmonization Analysis working group to analyze internal
and external CGMP requirements, including those related to quality
systems. The working group performed a formal analysis of parts 210 and
211 compared with other regulations, such as the FDA Medical Device
Quality System Requirements, the FDA Food Hazard Analysis and Critical
Control Points requirements, and the drug GMPs of the European Union,
to identify the differences and consider the value of adding or
changing the current regulations in light of these more recently
developed and related product manufacturing standards.
Based on the working group's analysis, the agency decided that a
different approach to revising the CGMP regulations was appropriate,
and has decided to withdraw the proposed rule.
II. New Approach to Revising FDA's CGMP Regulations
The emphasis of the new approach to CGMP arising from the 21st
Century Initiative will be to encourage timely detection of and
response to emerging adverse trends or indications that product quality
has been compromised, to provide further clarity and modernize the
regulations, and to harmonize various aspects of parts 210 and 211 both
internationally and with other agency regulations.\1\
---------------------------------------------------------------------------
\1\See Pharmaceutical CGMPs for the 21st Century--A Risk Based
Approach; Final Report, September, 2004; available at https://
www.fda.gov/cder/gmp/gmp2004/GMP_finalreport2004.htm.
---------------------------------------------------------------------------
The agency has determined that the current CGMP regulations (parts
210 and 211) provide a degree of flexibility that will permit the
agency to continue to modernize its approach to regulation of CGMP. The
agency has also concluded that, as stated in the final report on the
21st Century initiative, given this new approach to regulation of
pharmaceutical CGMP, it would be preferable to revise the CGMP
regulations in an incremental fashion, rather than using the
comprehensive approach taken in the May 1996 proposed rule. After
careful consideration, FDA concludes that at this time, it is
appropriate to withdraw the May 1996 proposed rule and newly evaluate
the issues raised in that proposal in the context of more recent
scientific and technical advances and quality systems and risk
management concepts.
We plan to revise the CGMP regulations using a more incremental
approach. As part of the FDA's incremental approach to revising our
CGMP regulations, we are publishing a direct final rule (and a
companion proposed rule) elsewhere in this issue of the Federal
Register that will, when finalized, clarify and modernize certain
provisions in parts 210 and 211. That direct final rule and proposed
rule include some of the minor changes to CGMP that were originally
proposed in 1996.
III. Comments on the May 1996 Proposed Rule
FDA received approximately 1,500 comments on the May 1996 proposed
rule from 116 pharmaceutical companies, attorneys, consultants, trade
associations, and generic companies. The most significant topics on
which FDA received comments are summarized as follows:
Approximately 298 comments addressed the proposed new
section on process validation (Sec. 211.220). The volume and variety
of comments and suggestions indicated to FDA that the new section, as
proposed, did not provide the clarification intended.
Approximately 102 comments were directed at the proposed
changes to Sec. 211.110 on sampling and testing of in-process
materials and drug products, which would have added new in-process
sampling and validation requirements with respect to blend uniformity.
The bulk of these comments questioned the need for additional testing
and sampling requirements in Sec. 211.110, because other sections of
the current rule already require scientifically sound sampling plans
and representative samples.
Approximately 112 comments discussed proposed revisions to
Sec. 211.192 on the production, control, and laboratory review, and
investigation of discrepancies. The May 1996 proposed rule required
written procedures to be established for the review of certain records
and investigation of unexplained discrepancies. Many of these comments
recommended that these investigations and reviews should be used to
proactively prevent (potential) future problems rather than being used
only to retroactively identify manufacturing discrepancies.
A number of comments to the rule were submitted by the
compressed medical gas industry, which communicated concerns regarding
the applicability to the compressed medical gas industry of the
proposed changes to CGMP.
[[Page 68113]]
Approximately 70 comments were received regarding the
proposed new Sec. 211.240 on control of chemical and physical
contaminants. Many of the comments stated that the rule should be
revised to better describe how contaminants will be identified and to
provide allowances for threshold levels or limits of contaminants.
Overall, the comments were constructive, informative, and addressed
nearly every area of the May 1996 proposed rule. Although we do not
plan to publish specific responses to each of these comments, we will
take these comments into account as we proceed to make incremental
changes to parts 210 and 211.
IV. Withdrawal of the Proposed Rule
For the reasons described in this document, FDA is withdrawing the
proposed rule published on May 3, 1996 (61 FR 20103).
Dated: November 26, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-23271 Filed 12-3-07; 8:45 am]
BILLING CODE 4160-01-S
